SCHEMBL431201

SCHEMBL431201

CC[Si](CC)(O[Si](CC)(CC)C(C)C)C(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4999736 0.78
SCHEMBL15916071 0.78
SCHEMBL15915282 0.75
SCHEMBL28728889 0.75
SCHEMBL4999749 0.75 LMNA (0.32)
SCHEMBL25404733 0.75
SCHEMBL15915373 0.75
SCHEMBL25405279 0.71
SCHEMBL25405552 0.71
SCHEMBL25401617 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 464 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8334099-B2 Nucleic acid amplification using a reversibly modified oligonucleotide BI WANLI (US) 2012-12-18 US claimed
EP-2049689-B1 NUCLEIC ACID AMPLIFICATION USING A REVERSIBLY MODIFIED OLIGONUCLEOTIDE BI WANLI (US) 2011-12-21 EP claimed
EP-1979362-B1 NOVEL SILANE COMPOUNDS AND USE THEREOF IN ORDER TO FUNCTIONALISE SOLID MEDIA AND IMMOBILISE BIOLOGICAL MOLECULES ON SAID MEDIA COMMISSARIAT ENERGIE ATOMIQUE (FR) 2010-12-15 EP claimed
US-20100021970-A1 Nucleic Acid Amplification Using a Reversibly Modified Oligonucleotide BI WANLI 2010-01-28 US claimed
EP-2049689-A2 NUCLEIC ACID AMPLIFICATION USING A REVERSIBLY MODIFIED OLIGONUCLEOTIDE Bi, Wanli (US) 2009-04-22 EP claimed
US-20090005269-A1 Novel Silane Compounds and Their Use in Functionalizing Solid Supports and Immobilizing Biological Molecules on These Supports CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2009-01-01 US claimed
EP-1979362-A1 NOVEL SILANE COMPOUNDS AND USE THEREOF IN ORDER TO FUNCTIONALISE SOLID MEDIA AND IMMOBILISE BIOLOGICAL MOLECULES ON SAID MEDIA COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 2008-10-15 EP claimed
EP-1889840-A1 Rearrangement of spirolactams LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2008-02-20 EP claimed
WO-2008016562-A2 NUCLEIC ACID AMPLIFICATION USING A REVERSIBLY MODIFIED OLIGONUCLEOTIDE BI WANLI (US) 2008-02-07 WO claimed
WO-2008009695-A1 REARRANGEMENT OF SPIROLACTAMS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2008-01-24 WO claimed
WO-2007088186-A1 NOVEL SILANE COMPOUNDS AND USE THEREOF IN ORDER TO FUNCTIONALISE SOLID MEDIA AND IMMOBILISE BIOLOGICAL MOLECULES ON SAID MEDIA COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 2007-08-09 WO claimed
EP-3494996-B1 ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS AGENSYS INC (US) 2026-04-15 EP disclosed
US-20260034234-A1 ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS AGENSYS, INC. (US) 2026-02-05 US disclosed
US-20260000604-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF AGENSYS, INC. (US) 2026-01-01 US disclosed
US-12496353-B2 Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway SEAGEN INC. (US) 2025-12-16 US disclosed
WO-1998049156-A1 PROCESSES FOR PREPARING BENZOTHIOPHENES ELI LILLY AND COMPANY (US) 1998-11-05 WO disclosed
WO-1998048787-A1 INTERMEDIATES AND A PROCESS FOR PREPARING BENZO[b]THIOPHENES ELI LILLY AND COMPANY (US) 1998-11-05 WO disclosed
WO-1998048793-A1 INTERMEDIATES AND PROCESSES FOR PREPARING BENZO[b]THIOPHENES ELI LILLY AND COMPANY (US) 1998-11-05 WO disclosed
EP-0875510-A1 Process for preparing benzothiophenes ELI LILLY AND COMPANY (US) 1998-11-04 EP disclosed
EP-0875507-A1 Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceuticals ELI LILLY AND COMPANY (US) 1998-11-04 EP disclosed